News

Filter

Current filters:

palonosetron

FDA approves Eisai’s Akynzeo for CINV

13-10-2014

The US Food and Drug Administration has approved Japanese pharma major Eisai’s Akynzeo (netupitant…

AkynzeoEisaiHelsinnnetupitantOncologypalonosetronPharmaceuticalRegulationUSA

Chugai gains marketing rights for Helsinn’s palonosetron and NEPA for chemo nausea

Chugai gains marketing rights for Helsinn’s palonosetron and NEPA for chemo nausea

17-07-2014

Japanese drugmaker Chugai, which is majority-owned by Swiss drug major Roche, has gained marketing rights…

AloxiAntiemeticsChemotherapy-induced nauseaChugai PharmaceuticalHelsinnOncologypalonosetron

Helsinn and Mundipharma collaborate on netupitant-palonosetron for China

Helsinn and Mundipharma collaborate on netupitant-palonosetron for China

23-12-2013

Privately-held Swiss drugmakers Helsinn and Mundipharma have signed a new, exclusive license and distribution…

Asia-PacificChinaHelsinnLicensingMundipharmanetupitantOncologypalonosetronPharmaceutical

Vifor gets certain rights to Helsinn's netupitant-palonosetron

16-05-2013

Privately-held Helsinn Healthcare and fellow Switzerland-based Vifor Pharma, part of the Galenica group…

EisaiEuropeGalenicaHelsinnLicensingnetupitantOncologypalonosetronPharmaceuticalVifor Pharma

Helsinn out-licenses netupitant-palonosetron fixed dose combo in South Korea

25-09-2012

Privately-held Swiss company Helsinn Group says it has signed a license agreement with CJ CheilJedang…

Asia-PacificHelsinnLicensingnetupitantOncologypalonosetronPharmaceutical

Eisai/Helsinn's Aloxi capsules approved in USA

01-09-2008

Japanese drugmaker Eisai and its partner, Switzerland's Helsinn Healthcare SA, say that the US Food and…

AloxiAloxi CapsulesAmino AcidsEisaiInjectionNystatinOralpalonosetronPalonosetron hydrochloridePhysostigmine Salicylate

COMPANY SPOTLIGHT

Menarini

Back to top